Literature DB >> 28194440

Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.

Elodie Picarda1,2, Séverine Bézie1,2, Laetitia Boucault1,2, Elodie Autrusseau1,2, Stéphanie Kilens1,2, Dimitri Meistermann1,2, Bernard Martinet1,2, Véronique Daguin1,2, Audrey Donnart3, Eric Charpentier3, Laurent David1,2, Ignacio Anegon1,2, Carole Guillonneau1,2.   

Abstract

Rat and human CD4+ and CD8+ Tregs expressing low levels of CD45RC have strong immunoregulatory properties. We describe here that human CD45 isoforms are nonredundant and identify distinct subsets of cells. We show that CD45RC is not expressed by CD4+ and CD8+ Foxp3+ Tregs, while CD45RA/RB/RO are. Transient administration of a monoclonal antibody (mAb) targeting CD45RC in a rat cardiac allotransplantation model induced transplant tolerance associated with inhibition of allogeneic humoral responses but maintained primary and memory responses against cognate antigens. Anti-CD45RC mAb induced rapid death of CD45RChigh T cells through intrinsic cell signaling but preserved and potentiated CD4+ and CD8+ CD45RClow/- Tregs, which are able to adoptively transfer donor-specific tolerance to grafted recipients. Anti-CD45RC treatment results in distinct transcriptional signature of CD4+ and CD8+ CD45RClow/- Tregs. Finally, we demonstrate that anti-human CD45RC treatment inhibited graft-versus-host disease (GVHD) in immune-humanized NSG mice. Thus, short-term anti-CD45RC is a potent therapeutic candidate to induce transplantation tolerance in human.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28194440      PMCID: PMC5291739          DOI: 10.1172/jci.insight.90088

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  61 in total

1.  Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection.

Authors:  Cécile Guillot; Carole Guillonneau; Patrick Mathieu; Christian A Gerdes; Séverine Ménoret; Cécile Braudeau; Laurent Tesson; Karine Renaudin; Maria G Castro; Pedro R Löwenstein; Ignacio Anegon
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

2.  Prevention of diabetes mellitus in the non-obese diabetic mouse strain with monoclonal antibodies against the CD45RB molecule.

Authors:  M M Abu-Hadid; A I Lazarovits; J Madrenas
Journal:  Autoimmunity       Date:  2000       Impact factor: 2.815

Review 3.  CD45: a critical regulator of signaling thresholds in immune cells.

Authors:  Michelle L Hermiston; Zheng Xu; Arthur Weiss
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 4.  CD8+ regulatory T cells in solid organ transplantation.

Authors:  Carole Guillonneau; Elodie Picarda; Ignacio Anegon
Journal:  Curr Opin Organ Transplant       Date:  2010-12       Impact factor: 2.640

5.  CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset.

Authors:  Markus Kleinewietfeld; Fabiola Puentes; Giovanna Borsellino; Luca Battistini; Olaf Rötzschke; Kirsten Falk
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

6.  Prolongation of allograft survival by administration of anti-CD45RB monoclonal antibody is due to alteration of CD45RBhi: CD45RBlo T-cell proportions.

Authors:  P P W Luke; J P Deng; D Lian; P J O'Connell; B Garcia; A M Jevnikar; R Zhong
Journal:  Am J Transplant       Date:  2006-07-06       Impact factor: 8.086

7.  The transcription cofactor Hopx is required for regulatory T cell function in dendritic cell-mediated peripheral T cell unresponsiveness.

Authors:  Daniel Hawiger; Yisong Y Wan; Elizabeth E Eynon; Richard A Flavell
Journal:  Nat Immunol       Date:  2010-08-29       Impact factor: 25.606

8.  CD7 and CD28 are required for murine CD4+CD25+ regulatory T cell homeostasis and prevention of thyroiditis.

Authors:  Gregory D Sempowski; Scott J Cross; Craig S Heinly; Richard M Scearce; Barton F Haynes
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

9.  Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens.

Authors:  M Streuli; L R Hall; Y Saga; S F Schlossman; H Saito
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells.

Authors:  Séverine Bézie; Elodie Picarda; Laurent Tesson; Karine Renaudin; Justine Durand; Séverine Ménoret; Emmanuel Mérieau; Elise Chiffoleau; Carole Guillonneau; Lise Caron; Ignacio Anegon
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

View more
  22 in total

1.  In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients.

Authors:  Séverine Bézie; Claire Usal; Carole Guillonneau
Journal:  J Vis Exp       Date:  2017-08-12       Impact factor: 1.355

2.  Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.

Authors:  Séverine Bézie; Béatrice Charreau; Nadège Vimond; Juliette Lasselin; Nathalie Gérard; Véronique Nerrière-Daguin; Frédérique Bellier-Waast; Franck Duteille; Ignacio Anegon; Carole Guillonneau
Journal:  Blood Adv       Date:  2019-11-26

Review 3.  Neuroinflammation: Extinguishing a blaze of T cells.

Authors:  Nail Benallegue; Hania Kebir; Jorge I Alvarez
Journal:  Immunol Rev       Date:  2022-07-31       Impact factor: 10.983

4.  Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease.

Authors:  Laetitia Boucault; Maria-Dolores Lopez Robles; Allan Thiolat; Séverine Bézie; Michael Schmueck-Henneresse; Cécile Braudeau; Nadège Vimond; Antoine Freuchet; Elodie Autrusseau; Frédéric Charlotte; Rabah Redjoul; Florence Beckerich; Mathieu Leclerc; Eliane Piaggio; Regis Josien; Hans-Dieter Volk; Sébastien Maury; José L Cohen; Ignacio Anegon; Carole Guillonneau
Journal:  Blood Adv       Date:  2020-06-09

5.  Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/- Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice.

Authors:  Séverine Bézie; Dimitri Meistermann; Laetitia Boucault; Stéphanie Kilens; Johanna Zoppi; Elodie Autrusseau; Audrey Donnart; Véronique Nerrière-Daguin; Frédérique Bellier-Waast; Eric Charpentier; Franck Duteille; Laurent David; Ignacio Anegon; Carole Guillonneau
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

6.  Equal Expansion of Endogenous Transplant-Specific Regulatory T Cell and Recruitment Into the Allograft During Rejection and Tolerance.

Authors:  James S Young; Dengping Yin; Augustin Georges Louis Vannier; Maria-Luisa Alegre; Anita S Chong
Journal:  Front Immunol       Date:  2018-06-20       Impact factor: 7.561

Review 7.  Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer.

Authors:  Martha R Vieyra-Lobato; Jorge Vela-Ojeda; Laura Montiel-Cervantes; Rubén López-Santiago; Martha C Moreno-Lafont
Journal:  J Immunol Res       Date:  2018-08-05       Impact factor: 4.818

8.  Pre-transplant CD45RC expression on blood T cells differentiates patients with cancer and rejection after kidney transplantation.

Authors:  Anne-Sophie Garnier; Martin Planchais; Jérémie Riou; Clément Jacquemin; Laurence Ordonez; Jean-Paul Saint-André; Anne Croue; Abdelhadi Saoudi; Yves Delneste; Anne Devys; Isabelle Boutin; Jean-François Subra; Agnès Duveau; Jean-François Augusto
Journal:  PLoS One       Date:  2019-03-29       Impact factor: 3.240

Review 9.  Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

Authors:  Lingling Zhang; Jianhua Yu; Wei Wei
Journal:  Front Immunol       Date:  2018-05-16       Impact factor: 7.561

Review 10.  Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.

Authors:  Priscila Ferreira Slepicka; Mahboubeh Yazdanifar; Alice Bertaina
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.